Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2004

View Archived Issues

Canadian approval for Humira

Celgene and Galapagos sign up for target discovery collaboration

Medicure to develop MC-1/ARB combination product

New European study for TheraCIM in pancreatic cancer

AstraZeneca reconfirms safety of Crestor

Approval for Atrovent HFA

Positive opinion handed down for Prialt in Europe

Phase I studies completed for aerosolized hydroxychloroquine

European orphan drug designation for Aplidin for multiple myeloma

Morphochem and Probiodrug to develop DPP-IV inhibitors

Dyax and Epix form new peptide collaboration

CA4P enters phase II study

Improved antimicrobial activity of novel dihydrothiazine phenyloxazolidinones

Preclinical and clinical efficacy of dextofisopam reported for IBS and IBD

Preclinical efficacy of rosiglitazone in reducing cutaneous inflammation in psoriasis

Preclinical characterization and pharmacokinetics of a novel lincosamide VIC-5555

Novel 17beta-HSD inhibitors designed by Sterix

Preclinical characterization and pharmacokinetics of a novel peptide deformylase inhibitor, LBM-415

Cannabinoid CB2 receptor modulators described in a patent

IRM patents cathepsin D inhibitors for rheumatoid arthritis, osteoarthritis, inflammation, etc.

Merck presents series of sodium channel blockers

Dual acting piperidine derivatives claimed by AstraZeneca

Antitumor treatments described in patent literature

Cardioprotective effects of K+ channel blocker from Aventis

Selective nicotinic receptor partial agonist for the treatment of AD and schizophrenia

Direct positive inotropic action on cardiac myosin may improve therapy for congestive heart failure

Nicotinic receptor agonist shows procognitive activity

Atlizumab shows efficacy in the treatment of systemic-onset juvenile idiopathic arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...